Top Ranked Momentum Stocks to Buy for November 22nd
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 22nd:
Garmin Ltd. (GRMN): This company that designs, develops, manufactures, markets, and distributes a range of navigation, communication, and information devices has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.7% over the last 60 days.
Garmin Ltd. Price and Consensus
Garmin Ltd. price-consensus-chart | Garmin Ltd. Quote
Garmin’s shares gained 12.2% over the last one month above the S&P 500’s increase 3.6%. The company possesses a Momentum Score of A.
Garmin Ltd. Price
Garmin Ltd. price | Garmin Ltd. Quote
Ultra Clean Holdings, Inc. (UCTT): This company that designs, develops, prototypes, engineers, manufactures, and tests production tools, modules, and subsystems for the semiconductor and display capital equipment industries has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 13% over the last 60 days.
Ultra Clean Holdings, Inc. Price and Consensus
Ultra Clean Holdings, Inc. price-consensus-chart | Ultra Clean Holdings, Inc. Quote
Ultra Clean Holdings’ shares gained 33.6% over the last one month. The company possesses a Momentum Score of A.
Ultra Clean Holdings, Inc. Price
Ultra Clean Holdings, Inc. price | Ultra Clean Holdings, Inc. Quote
Amedisys, Inc. (AMED): This company provides healthcare services has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.5% over the last 60 days.
Amedisys, Inc. Price and Consensus
Amedisys, Inc. price-consensus-chart | Amedisys, Inc. Quote
Amedisys’ shares gained 16.9% over the last one month. The company possesses a Momentum Score of A.
Amedisys, Inc. Price
Amedisys, Inc. price | Amedisys, Inc. Quote
DaVita Inc. (DVA): This company that provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 10.6% over the last 60 days.
DaVita Inc. Price and Consensus
DaVita Inc. price-consensus-chart | DaVita Inc. Quote
DaVita’s shares gained 21.8% over the last one month. The company possesses a Momentum Score of A.
DaVita Inc. Price
DaVita Inc. price | DaVita Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ultra Clean Holdings, Inc. (UCTT) : Free Stock Analysis Report
Garmin Ltd. (GRMN) : Free Stock Analysis Report
DaVita Inc. (DVA) : Free Stock Analysis Report
Amedisys, Inc. (AMED) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research